ALDX
Aldeyra Therapeutics Inc

8,325
Mkt Cap
$330.9M
Volume
1.02M
52W High
$7.20
52W Low
$1.14
PE Ratio
-7.62
ALDX Fundamentals
Price
$5.46
Prev Close
$5.50
Open
$5.46
50D MA
$5.00
Beta
2.80
Avg. Volume
875,589.45
EPS (Annual)
-$0.9389
P/B
6.72
Rev/Employee
$0.00
$210.98
Loading...
Loading...
News
all
press releases
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference
Aldeyra Therapeutics (NASDAQ:ALDX) CEO Todd Brady provided an update on the company's late-stage ophthalmology programs and broader pipeline during a fireside chat at Oppenheimer's 36th Annual...
MarketBeat·2d ago
News Placeholder
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Friday
Aldeyra Therapeutics (NASDAQ:ALDX) will be releasing its Q4 2025 earnings before the market opens on Friday, February 27. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?
The consensus price target hints at a 79.3% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·8d ago
News Placeholder
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving Average - Here's What Happened
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Below 200-Day Moving Average - Time to Sell...
MarketBeat·9d ago
News Placeholder
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...
Business Wire·10d ago
News Placeholder
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving Average - Should You Sell?
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above 50-Day Moving Average - Here's Why...
MarketBeat·17d ago
News Placeholder
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know
The consensus price target hints at a 65.8% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·24d ago
News Placeholder
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year?
Here is how Aldeyra Therapeutics, Inc. (ALDX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Zacks·24d ago
News Placeholder
PFG Investments LLC Reduces Stock Position in Aldeyra Therapeutics, Inc. $ALDX
PFG Investments LLC cut its stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 74.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange...
MarketBeat·30d ago
<
1
2
...
>

Latest ALDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.